MedTrace Logo

Betamethasone and Severity of Hyaline Membrane Disease

NCT01854840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2026-03-04

No results posted yet for this study

Summary

Primary purpose: to study the relationship between betamethasone placental transfer and the occurrence and severity of the Hyaline Membrane Disease.

Conditions

  • Pregnant Women Receive Celesten

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Yves Ville, MD, PhD · Necker Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-12
Primary Completion
2017-06-30
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854840 on ClinicalTrials.gov